In North America: Tuesday, 30 March 2021 at 12:00 PM Noon EDT / 9:00 AM PDT. Register here
In Europe: Tuesday, 30 March 2021 at 12:00 BST/ 13:00 CEST. Register here
Here we present the development and application two different innovative approaches to achieving physiologically relevant 3D models of human tissues.
First, we discuss an Alvetex scaffold-based technology that can be used to create advanced organotypic 3D models of various human tissue types that more closely resemble in vivo-like anatomical and physiological conditions. Various examples will be demonstrated using human skin and the intestinal mucosa. We provide evidence of how these models resemble the structure and function of native tissues, and their relevance to the development of more sophisticated physiologically relevant in vivo-like cell-based assays to model aspects of health and disease. For example, how bioengineered human skin can be developed to mimic aspects of the aging process, and how the inclusion of immune cells into an intestinal mucosal model can mimic features of inflammatory disorders such as Irritable Bowel Disease.
Next, we discuss the development of new models for cancer and drug development. As pharmaceutical therapies for diseases such as cancer become increasingly humanized in the development of personalized medicine, the traditional methods of preclinical testing become less relevant. The use of monolayer cultures has been effective in assessing the safety of small molecule drugs, but the disparity between 2D cultures and in vivo tissue biology proves too substantial for current potential therapies. Three-dimensional (3D) cultures have been shown to be more physiologically relevant models of in vivo tissue. However, generating consistent 3D cultures can be difficult. Further, they fail to fully mimic living tissue and suffer from the lack of active oxygen and nutrient transport. Lena Biosciences has developed a groundbreaking perfusion platform that facilitates long-term growth of complex 3D tissue models. In this webinar, attendees will learn about the advantages of perfused 3D cell culture and how the tools developed by Lena Biosciences can enable researchers to create cutting-edge tissue models applicable to all areas of biomedical research.
|Professor Stefan Przyborski holds an academic position as Professor in Cell Technology at Durham University. He has over 25 years experience in cell biology with specific interests in cell culture technology, tissue engineering and stem cell research. In recent years he has developed a multi-disciplinary approach through collaborative projects with physical scientists to develop novel ways of solving biological problems. He has formed alliances with pharmaceutical and biotech companies, has published over 125 scientific papers and has filed several patents. He is also the founder and Chief Scientific Officer of Reinnervate (now part of REPROCELL Europe), a biotechnology company founded in 2002 as a spinout from Durham University UK. Professor Przyborski is developing new and innovative ways to manage the growth and function of cultured cells. He is the inventor of Alvetex technology, the market leading scaffold product for three-dimensional cell culture. These enabling technologies have multiple applications and are particularly relevant to bioengineering models of human tissues to advance basic research, safety assessment and drug discovery.|
|Dr. James T. Shoemaker is an accomplished biomedical engineer with ten years of experience in development and application of three-dimensional (3D) tissue models in applied research and pharmaceutical testing. James is responsible for 3D cell-based assays, pre-clinical device R&D, scientific collaborations and partnering activities. He has published peer-reviewed articles focusing on tissue engineering, biomedical devices and biomaterials, and frequently presents at conferences and symposiums. James has developed an extraordinary number of forefront tissue models, using primary cells, secondary cells, and cell lines, spanning normal tissue models (brain, liver, kidney, bone, etc.) and diseased tissue models (neuroblastoma, cervical cancer, breast cancer, hepatoma, etc). Prior to joining Lena Biosciences, James held research positions at Emory University. Dr. Shoemaker holds a Ph.D. in Biomedical Engineering from Emory University and the Georgia Institute of Technology and a B.Sc. in Chemistry from the Georgia Institute of Technology.|